Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
Sensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Sensei Biotherapeutics (SNSE) Expected to Announce Quarterly Earnings on Friday
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Short Interest Up 1,973.5% in February
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sensei Biotherapeutics Stock Soars 230% After Faeth Deal
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement
Sensei Biotherapeutics (NASDAQ:SNSE) vs. Cynata Therapeutics (OTCMKTS:CYYNF) Critical Analysis
Egle Therapeutics Appoints John Celebi as Chief Executive Officer
What Sparked Sensei Biotherapeutics (SNSE) Stock's Nearly 63% After‑Hours Jump?
Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results
Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value
Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025
Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025
Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Sensei (SNSE) Q2 Loss Narrows 31%
Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
These 3 health tech stocks spiked 37% in a day; Time to buy?
Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025
Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors
What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock
Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference
Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences
Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference
Sensei Biotherapeutics to Present at Upcoming Conferences
Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101
EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member
Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting
Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium